Abstract
Purpose
The aim of the study is to assess the relationship between serum liver enzyme level,
hepatic virus infectious state, and standard uptake value of liver on 2-fluoro-2-deoxy-D-glucose
(FDG)-positron emission tomography (PET).
Material and Methods
It is the retrospective review study from September 2005 to September 2007. A total
of 354 healthy subjects referred from the Department of Community Medicine and Health
Examination Center of our hospital for health screening were reviewed retrospectively
and recruited for analysis. Whole-body FDG-PET, serum liver enzyme levels [aspartate
aminotransferase (AST) or SGOT and alanine aminotransferase (ALT) or SGPT], and hepatic
B (HBV)/hepatic C virus (HCV) infectious states by checking serum antibodies were
performed in all subjects. The mean and maximal values of standard uptake values (SUV)
of liver were calculated. The relationships between serum liver enzyme levels, hepatic
virus infectious states, and standard uptake values of liver on FDG-PET were evaluated.
Result
There is statistically significant positive correlation between SGOT/SGPT and SUV
of liver on FDG-PET. However, there are no significant differences in the SUV of liver
on FDG-PET between HBV/HCV infection and nonhepatic virus infection subjects.
Conclusion
High FDG uptake in the liver because of high level of SGOT/SGPT may lower the diagnostic
sensitivity of hepatic malignant or infectious lesions on FDG-PET. For avoiding false-negative
findings, careful evaluation of liver on FDG-PET and correlation with other clinical
manifestations should be recommended in patients with high level of SGOT/SGPT. Nevertheless,
neither HBV/HCV infectious states significantly influences on the SUV of liver on
FDG-PET.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- 18F FDG PET—applications in oncology.Rev Med Chir Soc Med Nat Iasi. 2002; 106: 14-23
- Evaluation of various hepatic lesions with positron emission tomography.Taehan Kan Hakhoe Chi. 2002; 8: 472-480
- Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients.Nucl Med Commun. 2005; 26: 671-687
- Pitfalls in PET/CT interpretation.Q J Nucl Med Mol Imaging. 2007; 51: 235-243
- Pitfalls in integrated CT-PET of the thorax: implications in oncologic imaging.J Thorac Imaging. 2006; 21: lll-22
- Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging.Semin Nucl Med. 2004; 34: 122-133
- Visualization of normal organs in whole-body FDG-PET imaging.Kaku Igaku. 1999; 36: 971-977
- Current status of FDG-PET for head and neck cancer.J Surg Oncol. 2008; 97: 649-652
- Whole-body PET/CT-mammography for staging breast cancer: initial results.Br J Radiol. 2008; 81: 743-748
- Recent developments in urologic oncology: positron emission tomography molecular imaging.Curr Opin Oncol. 2008; 20: 321-326
- Desmoplastic melanoma: true positive and false negative findings on F-18 FDG-PET/CT.Clin Nucl Med. 2008; 33: 562-564
- Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT.Clin Nucl Med. 2008; 33: 510-512
- False positive 18F-FDG PET scan in adrenal oncocytoma.Urol Int. 2008; 80: 444-447
- Malignant tumor with false negative 18F-FDG PET image.Zhonghua Zhong Liu Za Zhi. 2006; 28: 713-717
- Correlation between the intensity of breast FDG uptake and menstrual cycle.Acad Radiol. 2007; 14: 940-944
- Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography.Semin Nucl Med. 2007; 37: 154-172
- Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography.J Clin Invest. 1992; 89: 1958-1963
- Can fluorodeoxyglucose-positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma.Kaku Igaku. 1991; 28: 1353-1356
- Global epidemiology of hepatitis B virus.J Clin Gastroenterol. 2004; 38: S158-S168
- Prevalence of hepatitis B surface antigen carrier status among residents in the endemic area of chronic arsenicism in Taiwan.Anticancer Res. 1991; 11: 229-233
- Hepatitis C virus (HCV) infection: a systemic disease.Mol Aspects Med. 2008; 29: 85-95
- Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey.J Med Virol. 1999; 59: 290-296
- Evaluation of liver function tests in screening for intra-abdominal injuries.Ann Emerg Med. 1991; 20: 838-841
- Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease.Arch Intern Med. 2003; 163: 218-224
- The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis.Am J Gastroenterol. 2002; 97: 2855-2860
Article info
Publication history
Published online: July 23, 2009
Accepted:
May 1,
2009
Received:
March 10,
2009
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
